Compare Caprolactam Chem with Similar Stocks
Stock DNA
Commodity Chemicals
INR 22 Cr (Micro Cap)
12.00
13
0.00%
1.68
33.27%
4.15
Total Returns (Price + Dividend) 
Caprolactam Chem for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
News

Caprolactam Chemicals Ltd Downgraded to Sell Amid Technical Weakness and Fundamental Concerns
Caprolactam Chemicals Ltd, a micro-cap player in the commodity chemicals sector, has seen its investment rating downgraded from Hold to Sell as of 27 July 2026. This shift reflects a deterioration in technical indicators alongside mixed financial performance and valuation concerns, prompting a reassessment of the stock’s attractiveness for investors.
Read full news article
Caprolactam Chemicals Ltd Upgraded to Hold on Improved Technicals and Financial Performance
Caprolactam Chemicals Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and robust quarterly financial results. The upgrade, effective from 22 July 2026, is driven by a combination of enhanced technical trends, strong financial growth, attractive valuation metrics, and a stabilising quality outlook amid a challenging commodity chemicals sector.
Read full news articleAre Caprolactam Chemicals Ltd latest results good or bad?
Caprolactam Chemicals Ltd has reported its financial results for the quarter ended March 2026, showcasing a notable operational turnaround. The company achieved net sales of ₹3.07 crores, reflecting a year-on-year growth of 90.68% and a quarter-on-quarter increase of 19.92%. This significant revenue growth indicates a recovery trajectory following previous challenges. The net profit for the quarter stood at ₹0.84 crores, marking a return to profitability compared to a loss in the same quarter last year. This represents a substantial improvement in the company's financial health. The operating margin reached 54.07%, the highest in eight quarters, demonstrating effective cost management and operational efficiency. Additionally, the profit after tax (PAT) margin improved to 27.36%, a stark contrast to the negative margin reported in the previous year. Despite these positive operational metrics, Caprolactam C...
Read full news article Announcements 
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
02-Jul-2026 | Source : BSECompliance Certificate under Reg 74(5) of SEBI (Depositories and Participants) Regulations 2018
Closure of Trading Window
25-Jun-2026 | Source : BSEClosure of Trading Window
Announcement under Regulation 30 (LODR)-Newspaper Publication
01-Jun-2026 | Source : BSENewspaper Advertisement of the Audited Financial Result for Quarter ended 31 March 2026
Corporate Actions 
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 0 FIIs
Siddharth Shankarlal Bhanushali (22.98%)
Laxmidas V. Bhanushali (1.28%)
43.51%
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ
QoQ Growth in quarter ended Mar 2026 is 19.92% vs 8.47% in Dec 2025
QoQ Growth in quarter ended Mar 2026 is 90.91% vs 238.46% in Dec 2025
Half Yearly Results Snapshot (Standalone) - Sep'25
Growth in half year ended Sep 2025 is 73.59% vs -29.53% in Sep 2024
Growth in half year ended Sep 2025 is 313.04% vs -195.83% in Sep 2024
Nine Monthly Results Snapshot (Standalone) - Dec'25
YoY Growth in nine months ended Dec 2025 is 46.00% vs -7.07% in Dec 2024
YoY Growth in nine months ended Dec 2025 is 457.69% vs -425.00% in Dec 2024
Annual Results Snapshot (Standalone) - Mar'26
YoY Growth in year ended Mar 2026 is 56.68% vs -3.16% in Mar 2025
YoY Growth in year ended Mar 2026 is 347.89% vs -455.00% in Mar 2025






